L01XC02 · Antineoplastic and immunomodulating agents
Rituximab Mabion
Indications
Treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL).
Composition
- Active substance
- rituximab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rituximab Mabion
- Active substance
- rituximab
- ATC code
- L01XC02
- Therapeutic area
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Arthritis, Rheumatoid, Microscopic Polyangiitis
- Marketing authorisation holder
- Mabion Spolka Akcyjna
- Status
- Application withdrawn